Curaleaf says enhanced Aurora bid stands; faults Aurora board for Organigram diligence access

Curaleaf Holdings, Inc.

Curaleaf's enhanced premium offer, dated October 6, 2026, to buy all outstanding Aurora common shares remains outstanding; original circular dated August 18, 2026.
Curaleaf says Aurora's board granted Organigram due diligence access but refused to engage Curaleaf, which it calls a 'gross dereliction' of fiduciary duties.
Curaleaf says it is awaiting undisclosed terms of Organigram's alternative deal: any break fee, management and board composition, and investor rights granted to BAT.
Curaleaf notes neither Aurora nor Organigram said whether their transaction is dilutive or accretive to shareholders.
Curaleaf argues its bid offers better value, a stronger capital markets profile, greater certainty and speed to close, and greater synergies than a 'smaller, less liquid' Organigram.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.